GASTROPARESIS TREATMENT MARKET ANALYSIS

Gastroparesis Treatment Market Size and Trends

Global gastroparesis treatment market is estimated to be valued at USD 7.95 Bn in 2024 and is expected to reach USD 10.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031. The market growth is driven by increasing prevalence of gastroparesis globally.

To learn more about this report, request sample copy

Market Driver - Rising awareness regarding gastroparesis treatment

Gastroparesis, commonly known as delayed gastric emptying, is a condition where the stomach takes too long to empty its contents. For many years, it went undiagnosed or was confused with other gastrointestinal disorders. However, over the past decade, recognition of gastroparesis as a distinct clinical entity has improved tremendously due  to initiatives by patient advocacy groups who have helped spread awareness about the condition and its treatments. Support communities formed by patients on social media platforms have provided invaluable peer support for those suffering from gastroparesis. Through open discussions, reputed doctors and specialists have been able to address common myths and misconceptions about the disease. Their efforts have led to a better understanding that gastroparesis is not just a stomach problem but can severely impair quality of life, if left untreated. Individuals are now more knowledgeable about seeking timely medical help rather than suffering silently. Awareness drives conducted by advocacy organizations in collaboration with medical professionals have effectively reached both urban and rural populations. Educational campaigns through various online and offline mediums highlight the signs and symptoms of gastroparesis along with stressing the importance of early diagnosis. This allows patients to recognize warning signs in the early stages itself and get appropriate treatment before complications arise. Healthcare providers are also alert to include gastroparesis in their differential diagnosis for gastrointestinal disorders.

Growing research and development activities

 Increased funding and focus on gastroparesis research can drive the market growth. Several academic institutes and pharmaceutical companies have ramped up clinical trials for developing novel drugs and medical devices. While metformin and prokinetic agents form the mainstay of current gastroparesis treatment, their effectiveness is limited in advanced cases. This has driven the medical community to investigate new therapeutic avenues. A number of startups are working on formulating targeted drug formulations for selectively delivering medications to the stomach. Their technology aims to enhance drug solubility, permeability, and release kinetics for optimizing symptom relief. Several clinical-stage biologics are also being assessed for their efficacy in modulating vagal nerve activity and immune responses linked to gastroparesis. Researchers are leveraging advancements in biologics to design more selective and less invasive treatment protocols. Meanwhile, medical device giants have invested substantially in R&D of gastric electrical stimulation devices. New generation devices are being miniaturized for improved comfort and battery life. Some incorporate remote monitoring capabilities as well. Emerging neuromodulation platforms study applying spinal cord or vagal nerve stimulation techniques for gastroparesis. Accelerated evaluation of novel therapeutic strategies can address the unmet needs of gastroparesis patients globally.